Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Acquired Immunodeficiency Syndrome

Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. "Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis." J. Acquir. Immune Defic. Syndr.. 2007;46(4):402-9.
Swindells S, Jiang H, A Mukherjee L, Winters M, Bosch RJ, Katzenstein D. "Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis." HIV Clin Trials. 2011;12(2):79-88.
Tsibris AMN, Paredes R, Chadburn A, et al. "Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211." Clin. Infect. Dis.. 2009;48(5):642-9.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. "Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES." PLoS ONE. 2013;8(6):e65306.
Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. "Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms." AIDS. 2013;27(6):967-72.
Castillo-Mancilla JR, Cohn SE, Krishnan S, et al. "Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials." HIV Clin Trials. 2014;15(1):14-26.
Wohl DA, Kendall MA, Andersen J, et al. "Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030." HIV Clin Trials. 2009;10(3):143-52.
McComsey GA, Kitch D, Sax PE, et al. "Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202." J. Acquir. Immune Defic. Syndr.. 2014;65(2):167-74.
Genberg BL, Wilson IB, Bangsberg DR, et al. "Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America." AIDS. 2012;26(11):1415-23.
Skiest DJ, Su Z, Havlir DV, et al. "Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170." J. Infect. Dis.. 2007;195(10):1426-36.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.
Robbins GK, Spritzler JG, Chan ES, et al. "Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384." Clin. Infect. Dis.. 2009;48(3):350-61.
Motsinger AA, Ritchie MD, Shafer RW, et al. "Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study." Pharmacogenet. Genomics. 2006;16(11):837-45.
George E, Noël F, Bois G, et al. "Antiretroviral therapy for HIV-1-infected children in Haiti." J. Infect. Dis.. 2007;195(10):1411-8.
Messer K, Vaida F, Hogan C. "Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217." Contemp Clin Trials. 2006;27(6):506-17.
Wanga V, Venuto C, Morse GD, et al. "Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2015;25(9):450-61.
DiFrancesco R, Rosenkranz S, A Mukherjee L, et al. "Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial." Ther Drug Monit. 2010;32(4):458-66.
Eron JJ, Park J-G, Haubrich R, et al. "Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy." Antimicrob. Agents Chemother.. 2009;53(6):2335-41.
Wohl DA, Kendall MA, Feinberg J, et al. "The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit." PLoS ONE. 2013;8(11):e78676.
Robertson KR, Su Z, Margolis DM, et al. "Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort." Neurology. 2010;74(16):1260-6.
Clifford DB, Smurzynski M, Park LS, et al. "Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients." Neurology. 2009;73(4):309-14.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
Zolopa A, Andersen J, Powderly W, et al. "Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial." PLoS ONE. 2009;4(5):e5575.
Mugavero MJ, Pence BWells, Whetten K, et al. "Predictors of AIDS-related morbidity and mortality in a southern U.S. Cohort." AIDS Patient Care STDS. 2007;21(9):681-90.
Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Zhang X, Tierney C, Albrecht M, et al. "Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146." Ther Drug Monit. 2013;35(2):209-16.
Abbas UL, Anderson RM, Mellors JW. "Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings." J. Acquir. Immune Defic. Syndr.. 2006;41(5):632-41.
Godfrey CC, Michelow PM, Godard M, et al. "Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks." Am. J. Clin. Pathol.. 2013;140(6):881-9.
Huang X-L, Fan Z, Borowski L, Rinaldo CR. "Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity." J. Leukoc. Biol.. 2008;83(6):1530-40.
L Wheat J, Connolly P, Smedema M, et al. "Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole." J. Antimicrob. Chemother.. 2006;57(6):1235-9.

Pages